SSY Group Limited provided earnings guidance for the six months ended June 30, 2017. For the period, the profit attributable to equity holders of the Company for the six months ended 30 June 2017 is expected to increase significantly and record an increase of not less than 30% as compared with that of the same period of 2016. Such expected increase was mainly due to, among other things, (i) increases in sales volumes and average selling prices of intravenous infusion solutions, (ii) increase in the overall gross profit margin of the Group's products and (iii) the absence of expense for grant of options during the six months ended 30 June 2017, whereas there was a one-off expense incurred during the six months ended 30 June 2016 on grant of share options.